Do analysts rate SXTC or CNSP?

CNS Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 258.74%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CNS Pharmaceuticals is more favorable than China SXT Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, SXTC or CNSP?

China SXT Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio China SXT Pharmaceuticals $1.14M 1.48 -$6.20M N/A N/A CNS Pharmaceuticals N/A N/A -$15.85M -$23.59 N/A

Is SXTC or CNSP more profitable?

China SXT Pharmaceuticals' return on equity of 0.00% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets China SXT Pharmaceuticals N/A N/A N/A CNS Pharmaceuticals N/A -204.25% -141.87%

Do analysts rate SXTC or TRAW?

Traws Pharma has a consensus price target of $1.00, indicating a potential upside of 67.22%. Given Traws Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Traws Pharma is more favorable than China SXT Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Traws Pharma 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Which has better earnings and valuation, SXTC or TRAW?

Traws Pharma has lower revenue, but higher earnings than China SXT Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio China SXT Pharmaceuticals $1.14M 1.48 -$6.20M N/A N/A Traws Pharma N/A N/A $9.17M -$1.74 N/A

Is SXTC or TRAW more profitable?

China SXT Pharmaceuticals' return on equity of 0.00% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets China SXT Pharmaceuticals N/A N/A N/A Traws Pharma N/A -23,868.92% -165.52%

Does the media prefer SXTC or TRAW?

In the previous week, China SXT Pharmaceuticals had 1 more articles in the media than Traws Pharma. MarketBeat recorded 3 mentions for China SXT Pharmaceuticals and 2 mentions for Traws Pharma. China SXT Pharmaceuticals' average media sentiment score of 1.17 beat Traws Pharma's score of -0.63 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China SXT Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Traws Pharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Do analysts rate OBSV or SXTC?

Given ObsEva's higher probable upside, equities research analysts clearly believe ObsEva is more favorable than China SXT Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, OBSV or SXTC?

China SXT Pharmaceuticals has higher revenue and earnings than ObsEva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ObsEva N/A N/A -$58.38M -$0.92 N/A China SXT Pharmaceuticals $1.14M 1.48 -$6.20M N/A N/A

Is OBSV or SXTC more profitable?

China SXT Pharmaceuticals' return on equity of 0.00% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% China SXT Pharmaceuticals N/A N/A N/A

Do analysts recommend EGRX or SXTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, EGRX or SXTC?

Eagle Pharmaceuticals has higher revenue and earnings than China SXT Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eagle Pharmaceuticals $257.55M 0.03 $35.64M $1.18 0.51 China SXT Pharmaceuticals $1.14M 1.48 -$6.20M N/A N/A

Is EGRX or SXTC more profitable?

Company Net Margins Return on Equity Return on Assets Eagle Pharmaceuticals N/A N/A N/A China SXT Pharmaceuticals N/A N/A N/A

Does the media refer more to EGRX or SXTC?

In the previous week, China SXT Pharmaceuticals had 2 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 3 mentions for China SXT Pharmaceuticals and 1 mentions for Eagle Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 1.17 beat Eagle Pharmaceuticals' score of 0.00 indicating that China SXT Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eagle Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral China SXT Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate SXTC or CURX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, SXTC or CURX?

Curanex Pharmaceuticals has lower revenue, but higher earnings than China SXT Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio China SXT Pharmaceuticals $1.14M 1.48 -$6.20M N/A N/A Curanex Pharmaceuticals N/A N/A -$4.22M -$7.80 N/A

Is SXTC or CURX more profitable?

China SXT Pharmaceuticals' return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets China SXT Pharmaceuticals N/A N/A N/A Curanex Pharmaceuticals N/A -82.07% -79.65%

China SXT Pharmaceuticals (SXTC) Competitors

$3.53 -0.03 (-0.84%)

As of 02:23 PM Eastern

Compare

SXTC vs. CNSP, TRAW, OBSV, EGRX, and CURX

Should you buy China SXT Pharmaceuticals stock or one of its competitors? China SXT Pharmaceuticals's main competitors and comparable companies include CNS Pharmaceuticals (CNSP), Traws Pharma (TRAW), ObsEva (OBSV), Eagle Pharmaceuticals (EGRX), and Curanex Pharmaceuticals (CURX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does China SXT Pharmaceuticals compare to CNS Pharmaceuticals?

China SXT Pharmaceuticals (NASDAQ:SXTC) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CNS Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 258.74%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CNS Pharmaceuticals is more favorable than China SXT Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

China SXT Pharmaceuticals' return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China SXT Pharmaceuticals	N/A	N/A	N/A
CNS Pharmaceuticals	N/A	-204.25%	-141.87%

China SXT Pharmaceuticals has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.05, meaning that its share price is 205% more volatile than the broader market.

In the previous week, China SXT Pharmaceuticals had 2 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 3 mentions for China SXT Pharmaceuticals and 1 mentions for CNS Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 1.17 beat CNS Pharmaceuticals' score of 0.93 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
China SXT Pharmaceuticals	Positive
CNS Pharmaceuticals	Positive

China SXT Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China SXT Pharmaceuticals	$1.14M	1.48	-$6.20M	N/A	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A

Summary

China SXT Pharmaceuticals beats CNS Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Traws Pharma?

China SXT Pharmaceuticals (NASDAQ:SXTC) and Traws Pharma (NASDAQ:TRAW) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

Traws Pharma has a consensus price target of $1.00, indicating a potential upside of 67.22%. Given Traws Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Traws Pharma is more favorable than China SXT Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Traws Pharma	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 7.9% of Traws Pharma shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by insiders. Comparatively, 7.6% of Traws Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, China SXT Pharmaceuticals had 1 more articles in the media than Traws Pharma. MarketBeat recorded 3 mentions for China SXT Pharmaceuticals and 2 mentions for Traws Pharma. China SXT Pharmaceuticals' average media sentiment score of 1.17 beat Traws Pharma's score of -0.63 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China SXT Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Traws Pharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

China SXT Pharmaceuticals' return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China SXT Pharmaceuticals	N/A	N/A	N/A
Traws Pharma	N/A	-23,868.92%	-165.52%

Traws Pharma has lower revenue, but higher earnings than China SXT Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China SXT Pharmaceuticals	$1.14M	1.48	-$6.20M	N/A	N/A
Traws Pharma	N/A	N/A	$9.17M	-$1.74	N/A

China SXT Pharmaceuticals has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market.

Summary

China SXT Pharmaceuticals beats Traws Pharma on 6 of the 11 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to ObsEva?

ObsEva (NASDAQ:OBSV) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

ObsEva has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market.

China SXT Pharmaceuticals' return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
China SXT Pharmaceuticals	N/A	N/A	N/A

China SXT Pharmaceuticals has higher revenue and earnings than ObsEva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
China SXT Pharmaceuticals	$1.14M	1.48	-$6.20M	N/A	N/A

Given ObsEva's higher probable upside, equities research analysts clearly believe ObsEva is more favorable than China SXT Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, China SXT Pharmaceuticals had 3 more articles in the media than ObsEva. MarketBeat recorded 3 mentions for China SXT Pharmaceuticals and 0 mentions for ObsEva. China SXT Pharmaceuticals' average media sentiment score of 1.17 beat ObsEva's score of 0.00 indicating that China SXT Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
ObsEva	Neutral
China SXT Pharmaceuticals	Positive

17.5% of ObsEva shares are owned by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

China SXT Pharmaceuticals beats ObsEva on 8 of the 11 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Eagle Pharmaceuticals?

Eagle Pharmaceuticals (NASDAQ:EGRX) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Eagle Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market.

Eagle Pharmaceuticals has higher revenue and earnings than China SXT Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.51
China SXT Pharmaceuticals	$1.14M	1.48	-$6.20M	N/A	N/A

In the previous week, China SXT Pharmaceuticals had 2 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 3 mentions for China SXT Pharmaceuticals and 1 mentions for Eagle Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 1.17 beat Eagle Pharmaceuticals' score of 0.00 indicating that China SXT Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eagle Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
China SXT Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
China SXT Pharmaceuticals	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

China SXT Pharmaceuticals beats Eagle Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Curanex Pharmaceuticals?

China SXT Pharmaceuticals (NASDAQ:SXTC) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, China SXT Pharmaceuticals had 1 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 3 mentions for China SXT Pharmaceuticals and 2 mentions for Curanex Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 1.17 beat Curanex Pharmaceuticals' score of 0.39 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
China SXT Pharmaceuticals	Positive
Curanex Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by insiders. Comparatively, 39.7% of Curanex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

China SXT Pharmaceuticals' return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China SXT Pharmaceuticals	N/A	N/A	N/A
Curanex Pharmaceuticals	N/A	-82.07%	-79.65%

Curanex Pharmaceuticals has lower revenue, but higher earnings than China SXT Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China SXT Pharmaceuticals	$1.14M	1.48	-$6.20M	N/A	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$7.80	N/A

Summary

China SXT Pharmaceuticals beats Curanex Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

Get China SXT Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SXTC vs. The Competition

Export

Metric	China SXT Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.68M	$12.19B	$7.23B	$12.91B
Dividend Yield	N/A	2.61%	2.54%	11.02%
P/E Ratio	N/A	778.04	271.89	24.27
Price / Sales	1.48	792.59	609.79	79.60
Price / Cash	N/A	96.46	79.89	53.65
Price / Book	0.00	12.06	13.09	6.26
Net Income	-$6.20M	$2.81B	$3.46B	$347.96M
7 Day Performance	-3.17%	1.89%	2.03%	1.47%
1 Month Performance	-37.23%	5.60%	8.23%	4.69%
1 Year Performance	-99.98%	7.02%	26.31%	16.97%

China SXT Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SXTC China SXT Pharmaceuticals	1.0039 of 5 stars	$3.53 -0.8%	N/A	-100.0%	$1.69M	$1.14M	N/A	90	Short Interest Decrease Gap Down
CNSP CNS Pharmaceuticals	2.2829 of 5 stars	$5.83 -0.5%	$20.00 +243.1%	-11.1%	$8.51M	N/A	N/A	5	News Coverage Gap Up
TRAW Traws Pharma	1.9753 of 5 stars	$0.54 flat	$1.00 +85.2%	-57.4%	$8.18M	$2.79M	N/A	17	Positive News
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50
EGRX Eagle Pharmaceuticals	N/A	$0.60 flat	N/A	-78.5%	$7.73M	$257.55M	0.50	100	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SXTC) was last updated on 8/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

China SXT Pharmaceuticals (SXTC) Competitors

SXTC vs. CNSP, TRAW, OBSV, EGRX, and CURX

How does China SXT Pharmaceuticals compare to CNS Pharmaceuticals?

Summary

How does China SXT Pharmaceuticals compare to Traws Pharma?

Summary

How does China SXT Pharmaceuticals compare to ObsEva?

Summary

How does China SXT Pharmaceuticals compare to Eagle Pharmaceuticals?

Summary

How does China SXT Pharmaceuticals compare to Curanex Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC vs. The Competition

China SXT Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

China SXT Pharmaceuticals (SXTC) Competitors

SXTC vs. CNSP, TRAW, OBSV, EGRX, and CURX

How does China SXT Pharmaceuticals compare to CNS Pharmaceuticals?

Do insiders & institutionals hold more shares of SXTC or CNSP?

Do analysts rate SXTC or CNSP?

Is SXTC or CNSP more profitable?

Which has more risk and volatility, SXTC or CNSP?

Does the media prefer SXTC or CNSP?

Which has preferable earnings & valuation, SXTC or CNSP?

Summary

How does China SXT Pharmaceuticals compare to Traws Pharma?

Do analysts rate SXTC or TRAW?

Do insiders & institutionals hold more shares of SXTC or TRAW?

Does the media prefer SXTC or TRAW?

Is SXTC or TRAW more profitable?

Which has better earnings and valuation, SXTC or TRAW?

Which has more volatility & risk, SXTC or TRAW?

Summary

How does China SXT Pharmaceuticals compare to ObsEva?

Which has more volatility and risk, OBSV or SXTC?

Is OBSV or SXTC more profitable?

Which has preferable valuation & earnings, OBSV or SXTC?

Do analysts rate OBSV or SXTC?

Does the media refer more to OBSV or SXTC?

Do institutionals and insiders believe in OBSV or SXTC?

Summary

How does China SXT Pharmaceuticals compare to Eagle Pharmaceuticals?

Which has more risk and volatility, EGRX or SXTC?

Which has higher earnings & valuation, EGRX or SXTC?

Does the media refer more to EGRX or SXTC?

Do insiders & institutionals have more ownership in EGRX or SXTC?

Is EGRX or SXTC more profitable?

Do analysts recommend EGRX or SXTC?

Summary

How does China SXT Pharmaceuticals compare to Curanex Pharmaceuticals?

Does the media refer more to SXTC or CURX?

Do analysts rate SXTC or CURX?

Do institutionals & insiders hold more shares of SXTC or CURX?

Is SXTC or CURX more profitable?

Which has better earnings & valuation, SXTC or CURX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC vs. The Competition

China SXT Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools